GCP
PBE icon

GSA Capital Partners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

GSA Capital Partners’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$336K Hold
4,239
– – 0.02% 1182
2025
Q4 		$348K Buy
+4,239
New +$328K 0.03% 1086

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

GSA Capital Partners's PBE Position: Q1 2026 in Review

GSA Capital Partners held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 4,239 shares worth $336K. The position accounts for 0.02% of the portfolio, ranked #1182.

GSA Capital Partners first reported a position in PBE in Q4 2025 and has held it in 2 quarters since. The position peaked at $348K in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • GSA Capital Partners held 4,239 shares of Invesco Biotechnology & Genome ETF worth $336K as of Q1 2026.
  • GSA Capital Partners left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
  • Invesco Biotechnology & Genome ETF made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1182 holding.
  • GSA Capital Partners first reported a position in Invesco Biotechnology & Genome ETF in Q4 2025 and has held it in 2 quarters since.
  • GSA Capital Partners's Invesco Biotechnology & Genome ETF position peaked at $348K in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.